Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Lornamead Settles On Lice Claims; DASCA Introduced In House; FDA Warns Supplement Firms

This article was originally published in The Tan Sheet

Executive Summary

Lornamead settles false claims allegations; DASCA bill introduced in House; FDA warns three firms about unapproved drug claims; Actavis expands manufacturing; Valeant defends reputation, Allergan bid; Tom’s Of Maine launches Toddler Training Toothpaste; and FDA to host Nutrition and Supplement Facts labels.

You may also be interested in...



In Brief: Shasun Buys Nuprin, DSM And GSK Earnings, Ad Claims Referred To FTC

Shasun acquires ibuprofen products; DSM predicts nutrition sales will increase; GSK sales fall on supply chain trouble; Nature’s Medicine Associates’ ad referred to FTC; Heinrich co-sponsors designer steroid bill; and AHPA eases botanical identification burden.

In Brief: Nutrition Facts Update, Valeant Sales

FDA to update Nutrition and Supplement Facts labels; Valeant over performs in Q4, 2013; “probiotic” alone is a health claim, ASA; Troxyphen claims need modification, ERSP; and more In Brief.

Tom’s Of Maine Aims To Leverage Adult Sales Via Children’s Products

Tom’s of Maine expands its children’s oral care portfolio with two toothpastes and a fluoride mouth rinse partly with hopes of bringing their parents into the fold as well, an associate brand manager says. The firm also is launching a natural toothbrush.

Topics

Related Companies

UsernamePublicRestriction

Register

PS106952

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel